10-Q: Ensysce Biosciences Reports Q3 2024 Results, Fueled by Grant Funding and Equity Raises

Ensysce Biosciences saw a significant increase in federal grant revenue and completed multiple equity raises in Q3 2024, while research and development expenses decreased.

Summary

• Ensysce Biosciences reported a net income of $661,769 for the three months ended September 30, 2024, a significant turnaround from a net loss of $2,690,806 in the same period of 2023.
• The company's revenue was primarily driven by federal grants, which totaled $3,418,853 for the quarter, compared to $435,380 in the prior year.
• Research and development expenses decreased to $1,690,674 from $1,914,970 year-over-year.
• General and administrative expenses also saw a decrease, totaling $1,083,433 compared to $1,227,724 in the same quarter of 2023.
• The company completed a registered direct offering and warrant inducement in August 2024, raising approximately $1.67 million in gross proceeds.
• As of November 11, 2024, the company had 19,574,014 shares of common stock outstanding.

Sentiment

Score: 7

Explanation: The document shows a positive turn with a net income in Q3, increased grant funding, and successful capital raises. However, the company's history of losses, dependence on future funding, and the inherent risks of drug development temper the overall sentiment.

Positives

• The company achieved a net income in Q3 2024, a significant improvement from the net loss in the same period of the previous year.
• Federal grant funding increased substantially, providing a strong revenue stream.
• The company successfully raised capital through a registered direct offering and warrant inducement.
• Research and development expenses decreased, indicating improved cost management.
• The company's cash position improved significantly compared to the end of 2023.

Negatives

• The company has a history of operating losses and may continue to incur losses in the future.
• The company's ability to continue as a going concern is dependent on its ability to obtain adequate financing and achieve profitable operations.
• The company has not generated any product revenue and may not be able to develop or commercialize a marketable product.
• The company's future success is heavily reliant on the successful development and commercialization of its product candidates.

Risks

• The company's estimates regarding expenses, revenue, and capital requirements may not match actual amounts and timing.
• The company's lead product candidates may not be successful in limiting abuse, overdose, or misuse.
• The company needs substantial additional funding to complete the development and commercialization of its product candidates.
• Clinical trials may fail to replicate positive results from earlier studies.
• The company may be unable to successfully market or gain market acceptance of its product candidates.
• The company may be unable to obtain and maintain sufficient intellectual property protection.
• The company's common stock could be delisted from Nasdaq.
• The company may not be able to regain or maintain compliance with applicable listing standards of Nasdaq.

Future Outlook

The company expects to incur substantial expenses in the foreseeable future for the development and potential commercialization of its product candidates and ongoing internal research and development programs. The company's future viability is dependent on its ability to raise additional capital to finance its operations.

Management Comments

• The company's management believes that the information provided in the report is relevant to an assessment and understanding of the company's consolidated results of operations and financial condition.
• Management has concluded that the company's financial statements included in this Quarterly Report on Form 10-Q are fairly stated in all material respects in accordance with GAAP for each of the periods presented therein.

Industry Context

Ensysce Biosciences is operating in the pharmaceutical industry, specifically focusing on developing solutions for pain management with reduced potential for opioid abuse and overdose. This is a significant area of need, given the ongoing opioid crisis. The company's focus on abuse-deterrent and overdose-resistant technologies aligns with current industry trends and regulatory priorities.

Comparison to Industry Standards

• Ensysce's focus on abuse-deterrent and overdose-resistant opioid technologies is comparable to companies like Collegium Pharmaceutical and BioDelivery Sciences International, which also develop products aimed at reducing opioid misuse.
• The company's reliance on federal grants for funding is similar to other early-stage biotech companies that often leverage government funding to support research and development.
• The company's net loss per share of $(0.57) for the nine months ended September 30, 2024, is typical for a clinical-stage pharmaceutical company that has not yet commercialized any products.
• The company's cash position of $4.2 million as of September 30, 2024, is relatively low compared to larger pharmaceutical companies, highlighting the need for additional funding.

Related Party Transactions

• As of September 30, 2024, the Company held a $0.2 million senior secured convertible promissory note plus accrued interest and 0.4 million warrants exercisable for common stock at $1.5675 per share issued to a board member in connection to the issuance of the 2023 Notes.

Stakeholder Impact

• Shareholders may be encouraged by the company's improved financial performance and successful capital raises.
• Employees may benefit from the company's continued operations and potential growth.
• Customers (patients) may benefit from the development of new and safer pain management options.
• Suppliers and creditors may be impacted by the company's ability to meet its financial obligations.

Next Steps

• The company will continue preclinical studies and clinical trials for PF614, PF614-MPAR, and nafamostat.
• The company will advance the development of its product candidate pipeline.
• The company will seek regulatory approval for product candidates that successfully complete clinical trials.
• The company will undertake pre-commercialization activities to establish sales, marketing, and distribution capabilities.
• The company will continue to seek additional funding through public or private equity or debt financings or other sources.

Key Dates

Keywords

pharmaceutical, clinical stage, opioid, abuse-resistant, overdose protection, TAAP, MPAR, federal grants, equity offering, warrants, research and development